Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Idea to Innovation

University of Toronto

$125,000.00

Digital microfluidics for multiplexed cell-based screening

EF 2009-10

Résumé
We propose to develop a unique high-throughput screening tool that will be useful for early-stage pharmaceutical discovery. The new tool will rely on digital microfluidics (DMF), a technology in which droplets are manipulated on an open platform without any moving parts, valves or tubes. DMF enables fluid handling operations such as translating, merging, mixing and splitting of droplets, which can be utilized to perform large, parallel-scale bioassays. We propose to build a prototype instrument in which DMF-driven arrays of droplets containing mammalian cells are addressed with compounds from chemical libraries, and the potential drugs evaluated on the basis of observed changes in cells. The new method will facilitate 100-1000-fold reduction in reagent use, and will be compatible with standard laboratory instruments and infrastructure. We will demonstrate the utility of the new technique by implementing a pilot screen to discover "hits" with (potential) anti-cancer activity. This proposal is built on our preliminary work, in which we developed the first cell-based assays in droplets on a DMF platform. Working with The Innovation Group at the University of Toronto, we recently filed several patents describing these (and other) innovations related to digital microfluidics. This work has attracted the attention of several prospective industrial partners including Tecan Group Ltd. (an international leader in the liquid handling and multiplexed analysis markets) and the pharmaceutical giant, Eli Lilly. We hope that NSERC will fund this proposal, which will support the development of a new Canadian-grown technology that has the potential to revolutionize high-throughput screening and drug discovery.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
379832-2008
Name nom
Wheeler, Aaron
Department département
Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2008
Award amount
125000
Program id
I2IPJ
Program nane en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
1
Nb partie
1
Application title
Digital microfluidics for multiplexed cell-based screening
Keyword
NA
Application summary
We propose to develop a unique high-throughput screening tool that will be useful for early-stage pharmaceutical discovery. The new tool will rely on digital microfluidics (DMF), a technology in which droplets are manipulated on an open platform without any moving parts, valves or tubes. DMF enables fluid handling operations such as translating, merging, mixing and splitting of droplets, which can be utilized to perform large, parallel-scale bioassays. We propose to build a prototype instrument in which DMF-driven arrays of droplets containing mammalian cells are addressed with compounds from chemical libraries, and the potential drugs evaluated on the basis of observed changes in cells. The new method will facilitate 100-1000-fold reduction in reagent use, and will be compatible with standard laboratory instruments and infrastructure. We will demonstrate the utility of the new technique by implementing a pilot screen to discover "hits" with (potential) anti-cancer activity. This proposal is built on our preliminary work, in which we developed the first cell-based assays in droplets on a DMF platform. Working with The Innovation Group at the University of Toronto, we recently filed several patents describing these (and other) innovations related to digital microfluidics. This work has attracted the attention of several prospective industrial partners including Tecan Group Ltd. (an international leader in the liquid handling and multiplexed analysis markets) and the pharmaceutical giant, Eli Lilly. We hope that NSERC will fund this proposal, which will support the development of a new Canadian-grown technology that has the potential to revolutionize high-throughput screening and drug discovery.